Rigel Pharmaceuticals Inc (RIGL) shareholders
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.46−1.23 (-2.69%)
Close on Nov 13, 2026Market cap $830.51MP/E 2.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
87.7%
16M of 19M shares
Institutional holders
155
33 new, 26 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $305.87K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. Joint filing with Soleus Capital, LLC (9.90%), Soleus Capital Group, LLC (9.90%) and 3 more | 1,843,504 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (8.95%) | 1,672,000 | 8.95% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 1,381,983 | 7.70% | 13G (passive) amendment | Mar 31, 2025 |
| Soleus Capital, LLC Joint filing with Soleus Capital Master Fund, L.P. (6.40%), Soleus Capital Group, LLC (6.40%) and 3 more | 1,130,679 | 6.40% | 13G (passive) amendment | Dec 31, 2024 |
| Soleus Capital Management, L.P. Joint filing with Soleus Capital Master Fund, L.P. (5.20%), Soleus Capital, LLC (5.20%) and 3 more | 968,108 | 5.20% | 13G (passive) | May 6, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RIGL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,939,818 | 10.38% | $75.89M | +170,911 | 0.00% |
| Soleus Capital Management, L.P. | 1,843,504 | 9.87% | $72.12M | +1,833,504 | 2.49% |
| Armistice Capital, LLC | 1,672,000 | 8.95% | $65.41M | +392,000 | 0.80% |
| State Street Corp | 1,039,994 | 5.57% | $40.68M | −80,244 | 0.00% |
| Vanguard Capital Management LLC | 785,107 | 4.20% | $30.71M | +20,914 | 0.00% |
| American Century Companies Inc | 741,718 | 3.97% | $29.02M | +197,287 | 0.01% |
| Lsv Asset Management | 721,666 | 3.86% | $28.23M | +120,159 | 0.05% |
| Acadian Asset Management LLC | 591,686 | 3.17% | $23.14M | −74,740 | 0.03% |
| D. E. Shaw & Co., Inc. | 542,539 | 2.90% | $21.22M | +96,861 | 0.01% |
| Geode Capital Management, LLC | 483,175 | 2.59% | $18.91M | +42,549 | 0.00% |
| Marshall Wace, Llp | 367,393 | 1.97% | $14.37M | −230,985 | 0.01% |
| CM Management, LLC | 250,000 | 1.34% | $9.78M | +15,000 | 6.51% |
| Vanguard Portfolio Management LLC | 233,728 | 1.25% | $9.14M | +86,193 | 0.00% |
| Dimensional Fund Advisors LP | 227,951 | 1.22% | $8.92M | −151,590 | 0.00% |
| Goldman Sachs Group Inc | 226,780 | 1.21% | $8.87M | −212,321 | 0.00% |
| Two Sigma Investments, LP | 207,578 | 1.11% | $8.12M | −198,229 | 0.01% |
| Nomura Asset Management International Inc. | 195,000 | 1.04% | $7.63M | New | 0.01% |
| Morgan Stanley | 186,049 | 1.00% | $7.28M | +87,181 | 0.00% |
| Charles Schwab Investment Management Inc | 154,627 | 0.83% | $6.05M | −22,223 | 0.00% |
| Northern Trust Corp | 146,381 | 0.78% | $5.73M | +11,811 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 16M | 87.7% | 33 / 52 | 55 / 26 | 4M | 4M |
| Q1 2026 | 150 | 16M | 85.7% | 16 / 68 | 46 / 46 | 4M | 3M |
| Q4 2025 | 184 | 16M | 86.2% | 46 / 63 | 63 / 25 | 4M | 2M |
| Q3 2025 | 164 | 15M | 80.4% | 52 / 51 | 45 / 9 | 5M | 4M |
| Q2 2025 | 121 | 14M | 74.4% | 19 / 42 | 36 / 16 | 2M | 2M |
| Q1 2025 | 118 | 14M | 74.9% | 23 / 41 | 37 / 20 | 3M | 1M |
| Q4 2024 | 116 | 12M | 64.7% | 38 / 43 | 19 / 11 | 2M | 2M |
| Q3 2024 | 89 | 12M | 63.9% | 24 / 28 | 22 / 16 | 4M | 1M |
| Q2 2024 | 82 | 10M | 55.7% | 82 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
203 funds held RIGL in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RIGL | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 650,331 | 3.48% | $25.44M | 0.24% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 594,889 | 3.18% | $18.14M | 0.07% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 555,846 | 2.98% | $21.74M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 481,966 | 2.58% | $18.85M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 212,415 | 1.14% | $8.31M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 201,443 | 1.08% | $7.42M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 172,468 | 0.92% | $6.75M | 0.05% | Jun 30, 2026 |
| Nomura Healthcare Fund | 160,000 | 0.86% | $6.26M | 0.83% | Jun 30, 2026 |
| iShares Biotechnology ETF | 126,160 | 0.68% | $4.94M | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 94,115 | 0.50% | $2.87M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 91,913 | 0.49% | $2.80M | 0.02% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 91,888 | 0.49% | $3.59M | 0.06% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 90,858 | 0.49% | $2.77M | 0.05% | May 29, 2026 |
| Schwab U.S. Small-Cap ETF | 89,359 | 0.48% | $2.72M | 0.01% | May 31, 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 84,790 | 0.45% | $3.12M | 0.09% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Raul R. Rodriguez | CEO, President, Director | 273,362 | 1.46% | Sep 3, 2026 |
| Raymond J. Furey | EVP, GC, CCO & Corp Sec | 50,559 | 0.27% | Sep 3, 2026 |
| David A. Santos | EVP, Chief Commercial Officer | 61,622 | 0.33% | Sep 3, 2026 |
| Dean L. Schorno | EVP & Chief Financial Officer | 79,676 | 0.43% | Sep 3, 2026 |
| Alison L. Hannah | EVP, Chief Medical Officer | 35,025 | 0.19% | Jul 10, 2026 |
| Lisa Rojkjaer | EVP, Chief Medical Officer | 34,003 | 0.18% | Jun 22, 2026 |
| Kamil Ali-Jackson | Director | 10,125 | 0.05% | Jun 24, 2026 |
| Mark W. Frohlich | Director | 7,000 | 0.04% | May 19, 2026 |
| Walter H. Moos | Director | 18,472 | 0.10% | May 19, 2026 |
| Michael Patrick Miller | Director | 5,937 | 0.03% | May 19, 2026 |
| Jane Wasman | Director | 18,250 | 0.10% | May 19, 2026 |
| Anthony Gregg Lapointe | Director | 18,250 | 0.10% | May 19, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +620 | $18.70 | $11.59K | 79,676 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +2,000 | $24.20 | $48.40K | 81,676 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +1,286 | $24.20 | $31.12K | 82,962 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +694 | $12.70 | $8.81K | 79,056 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Sep 1, 2026 | Tax withholding | −877 | $47.50 | $41.66K | 50,559 |
| Raul R. Rodriguez CEO, President, Director | Sep 1, 2026 | Tax withholding | −2,424 | $47.50 | $115.14K | 273,362 |
| David A. Santos EVP, Chief Commercial Officer | Sep 1, 2026 | Tax withholding | −874 | $47.50 | $41.52K | 61,622 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 1, 2026 | Tax withholding | −928 | $47.50 | $44.08K | 78,362 |
| Alison L. Hannah EVP, Chief Medical Officer | Jul 8, 2026 | Award | +24,400 | – | – | 35,025 |
| Kamil Ali-Jackson Director | Jun 22, 2026 | Sale(10b5-1 plan) | −2,500 | $35.00 | $87.50K | 10,125 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Jun 1, 2026 | Tax withholding | −877 | $29.86 | $26.19K | 50,936 |
| Dean L. Schorno EVP & Chief Financial Officer | Jun 1, 2026 | Tax withholding | −928 | $29.86 | $27.71K | 78,790 |
| Dean L. Schorno EVP & Chief Financial Officer | Jun 1, 2026 | Option exercise | +2,181 | $12.70 | $27.70K | 79,718 |
| Dean L. Schorno EVP & Chief Financial Officer | Jun 1, 2026 | Option exercise | +1,200 | $18.70 | $22.44K | 77,537 |
| David A. Santos EVP, Chief Commercial Officer | Jun 1, 2026 | Tax withholding | −874 | $29.86 | $26.10K | 61,996 |
| Lisa Rojkjaer EVP, Chief Medical Officer | Jun 1, 2026 | Tax withholding | −850 | $29.86 | $25.38K | 34,003 |
| Raul R. Rodriguez CEO, President, Director | Jun 1, 2026 | Tax withholding | −2,424 | $29.86 | $72.38K | 279,593 |
| Kamil Ali-Jackson Director | May 26, 2026 | Sale(10b5-1 plan) | −2,500 | $29.17 | $72.93K | 12,625 |
| Walter H. Moos Director | May 15, 2026 | Award | +5,750 | – | – | 18,472 |
| Alison L. Hannah Director | May 15, 2026 | Award | +5,750 | – | – | 16,375 |
| Jane Wasman Director | May 15, 2026 | Award | +5,750 | – | – | 18,250 |
| Anthony Gregg Lapointe Director | May 15, 2026 | Award | +5,750 | – | – | 18,250 |
| Mark W. Frohlich Director | May 15, 2026 | Award | +5,750 | – | – | 7,000 |
| Michael Patrick Miller Director | May 15, 2026 | Award | +5,750 | – | – | 5,937 |
| Kamil Ali-Jackson Director | May 15, 2026 | Award | +5,750 | – | – | 15,125 |
| Walter H. Moos Director | Feb 20, 2026 | Sale | −4,000 | $36.36 | $145.44K | 12,722 |
| Walter H. Moos Director | Feb 20, 2026 | Option exercise | +4,000 | $24.00 | $96.00K | 16,722 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 17, 2026 | Award | +19,497 | – | – | 51,813 |
| Lisa Rojkjaer EVP, Chief Medical Officer | Feb 17, 2026 | Award | +18,894 | – | – | 34,853 |
| Raul R. Rodriguez CEO, President, Director | Feb 17, 2026 | Award | +53,915 | – | – | 282,017 |
| David A. Santos EVP, Chief Commercial Officer | Feb 17, 2026 | Award | +19,430 | – | – | 62,870 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 17, 2026 | Award | +20,636 | – | – | 76,337 |
| David A. Santos EVP, Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −3,546 | $34.62 | $122.76K | 43,440 |
| Raul R. Rodriguez CEO, President, Director | Feb 10, 2026 | Tax withholding | −7,607 | $34.62 | $263.35K | 228,102 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 10, 2026 | Tax withholding | −3,546 | $34.62 | $122.76K | 55,701 |
| Lisa Rojkjaer EVP, Chief Medical Officer | Feb 10, 2026 | Tax withholding | −3,758 | $34.62 | $130.10K | 15,959 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 10, 2026 | Tax withholding | −3,546 | $34.62 | $122.76K | 32,316 |
| David A. Santos EVP, Chief Commercial Officer | Feb 2, 2026 | Tax withholding | −5,718 | $36.01 | $205.91K | 46,986 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 2, 2026 | Tax withholding | −3,968 | $36.01 | $142.89K | 35,862 |
| Raul R. Rodriguez CEO, President, Director | Feb 2, 2026 | Tax withholding | −14,110 | $36.01 | $508.10K | 235,709 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 2, 2026 | Tax withholding | −5,488 | $36.01 | $197.62K | 59,247 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Tax withholding | −35,211 | $37.00 | $1.30M | 245,243 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Option exercise | +40,000 | $27.40 | $1.10M | 280,454 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Option exercise | +40,000 | $27.40 | $1.10M | 285,243 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Tax withholding | −35,424 | $37.00 | $1.31M | 249,819 |
| Dean L. Schorno EVP & Chief Financial Officer | Dec 22, 2025 | Option exercise | +1,987 | $20.00 | $39.74K | 59,722 |
| Dean L. Schorno EVP & Chief Financial Officer | Dec 22, 2025 | Option exercise | +2,846 | $24.20 | $68.87K | 62,568 |
| Dean L. Schorno EVP & Chief Financial Officer | Dec 22, 2025 | Option exercise | +1,667 | $18.70 | $31.17K | 64,235 |
| Walter H. Moos Director | May 23, 2025 | Award | +2,500 | – | – | 12,722 |
| Alison L. Hannah Director | May 23, 2025 | Award | +2,500 | – | – | 10,625 |
| Mark W. Frohlich Director | May 23, 2025 | Award | +1,250 | – | – | 1,250 |
| Kamil Ali-Jackson Director | May 23, 2025 | Award | +2,500 | – | – | 9,375 |
| Jane Wasman Director | May 23, 2025 | Award | +2,500 | – | – | 12,500 |
| Anthony Gregg Lapointe Director | May 23, 2025 | Award | +2,500 | – | – | 12,500 |
| David A. Santos EVP, Chief Commercial Officer | Feb 5, 2025 | Sale | −1,796 | $21.93 | $39.39K | 51,704 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 5, 2025 | Sale | −1,339 | $21.93 | $29.36K | 38,830 |
| Raul R. Rodriguez CEO, President, Director | Feb 5, 2025 | Sale | −4,400 | $21.93 | $96.49K | 239,454 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 5, 2025 | Sale | −1,734 | $21.93 | $38.03K | 57,235 |
| David A. Santos EVP, Chief Commercial Officer | Feb 4, 2025 | Sale | −2,125 | $20.92 | $44.46K | 53,500 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 4, 2025 | Sale | −1,448 | $20.92 | $30.29K | 40,169 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
14.03%
3M shares short
Days to cover
12.9
At 0M shares a day
Change since last report
-7.2%
From 3M shares
Short volume, 20 days
60.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Rigel Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 500 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kamil Ali-Jackson Director | Jun 22, 2026 | 2,500 | $87.50K | Jun 22, 2026 | Restricted Stock Vesting |
| Kamil Ali-Jackson Director | May 26, 2026 | 2,500 | $72.93K | May 26, 2026 | Restricted Stock Vesting |
| Walter H. Moos Director | Feb 20, 2026 | 4,000 | $145.44K | Feb 20, 2026 | Option Granted 05/11/2016 |
| Raymond J. Furey Officer | Feb 5, 2025 | 1,339 | $29.36K | Feb 5, 2025 | Restricted Stock Vesting |
| David A. Santos Officer | Feb 5, 2025 | 1,796 | $39.38K | Feb 5, 2025 | Restricted Stock Vesting |
| Raul R. Rodriguez Officer, Director | Feb 5, 2025 | 4,400 | $96.47K | Feb 5, 2025 | Restricted Stock Vesting |
| Dean L. Schorno Officer | Feb 5, 2025 | 1,734 | $38.02K | Feb 5, 2025 | Restricted Stock Vesting |
| Dean L. Schorno Officer | Feb 4, 2025 | 2,036 | $42.60K | Feb 4, 2025 | Restricted Stock Vesting |
| Raul R. Rodriguez Officer, Director | Feb 4, 2025 | 4,952 | $103.60K | Feb 4, 2025 | Restricted Stock Vesting |
| David A. Santos Officer | Feb 4, 2025 | 2,125 | $44.46K | Feb 4, 2025 | Restricted Stock Vesting |
| Raymond J. Furey Officer | Feb 4, 2025 | 1,448 | $30.29K | Feb 4, 2025 | Restricted Stock Vesting |
| Masuda Esteban Officer | Jan 24, 2025 | 4,999 | $110.68K | Jan 24, 2025 | Option Granted - 01/26/2015 |
See a number that looks wrong?